This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
G1 Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
G1 Therapeutics has a total shareholder equity of $24.6M and total debt of $44.3M, which brings its debt-to-equity ratio to 180.2%. Its total assets and total liabilities are $98.7M and $74.1M respectively.
Belangrijke informatie
180.2%
Verhouding schuld/eigen vermogen
US$44.32m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$60.73m |
| Aandelen | US$24.59m |
| Totaal verplichtingen | US$74.10m |
| Totaal activa | US$98.69m |
Recente financiële gezondheidsupdates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Analyse van de financiële positie
Kortlopende schulden: GTHX's short term assets ($92.9M) exceed its short term liabilities ($37.5M).
Langlopende schulden: GTHX's short term assets ($92.9M) exceed its long term liabilities ($36.6M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: GTHX has more cash than its total debt.
Schuld verminderen: GTHX's debt to equity ratio has increased from 0% to 180.2% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: GTHX has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if GTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.